Literature DB >> 8391919

Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines.

M L Slovak1, J P Ho, G Bhardwaj, E U Kurz, R G Deeley, S P Cole.   

Abstract

Two doxorubicin-selected human tumor cell lines, H69AR and HT1080/DR4, display a multidrug resistance phenotype but do not overexpress P-glycoprotein. Recently, a 6.5-kilobase mRNA encoding a novel member of the ATP-binding cassette superfamily of transport proteins, designated multidrug resistance-associated protein (MRP), has been identified in the H69AR cell line. In the present study, the levels of MRP mRNA were found to be 14-fold higher in HT1080/DR4 cells relative to sensitive HT1080 cells. Southern blotting indicates that gene amplification contributes to the overexpression of MRP in HT1080/DR4 cells. Using a 4-kilobase MRP complementary DNA probe, MRP genes were localized to 2-5 chromosomes bearing homogeneously staining regions and to multiple double minute chromosomes in H69AR cells. Resistant H69AR cells also contained a new der(16) with a structural aberration affecting 16p13.1, the normal cellular locus of the MRP gene. The MRP probe hybridized to two small homogeneously staining regions (hsr) in HT1080/DR4 cells including hsr(7)(p12p15). MRP localization was restricted to the normal cellular locus, 16p13.1, in the parental H69 and HT1080 cells and the drug-sensitive H69PR revertant cells. Our data provide combined evidence that amplification of the MRP gene is associated with the expression of drug resistance in selected solid tumor cell lines.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8391919

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy.

Authors:  C J Dimitroff; W Klohs; A Sharma; P Pera; D Driscoll; J Veith; R Steinkampf; M Schroeder; S Klutchko; A Sumlin; B Henderson; T J Dougherty; R J Bernacki
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

3.  Chromosome microdissection identifies genomic amplifications associated with drug resistance in a leukemia cell line: an approach to understanding drug resistance in cancer.

Authors:  Frouzandeh Mahjoubi; Ronald J Hill; Greg B Peters
Journal:  Chromosome Res       Date:  2006-04-20       Impact factor: 5.239

4.  The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.

Authors:  G J Zaman; M J Flens; M R van Leusden; M de Haas; H S Mülder; J Lankelma; H M Pinedo; R J Scheper; F Baas; H J Broxterman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

5.  Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein.

Authors:  D Alexander; T Yamamoto; S Kato; S Kasai
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

6.  Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia.

Authors:  M Kourti; N Vavatsi; N Gombakis; V Sidi; G Tzimagiorgis; T Papageorgiou; D Koliouskas; F Athanassiadou
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

7.  Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport.

Authors:  M Müller; C Meijer; G J Zaman; P Borst; R J Scheper; N H Mulder; E G de Vries; P L Jansen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

8.  Tissue distribution of the multidrug resistance protein.

Authors:  M J Flens; G J Zaman; P van der Valk; M A Izquierdo; A B Schroeijers; G L Scheffer; P van der Groep; M de Haas; C J Meijer; R J Scheper
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

Review 9.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 10.  Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro.

Authors:  B T Hill
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.